7:56 PM
 | 
Jun 03, 2013
 |  BC Extra  |  Clinical News

Merck reports ORR data for lambrolizumab in melanoma

Merck & Co. Inc. (NYSE:MRK) presented data at the American Society of Clinical Oncology meeting in Chicago showing that lambrolizumab ( MK-3475) led to an objective response rate (ORR) of 38% in 117 evaluable patients with advanced melanoma in...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >